NCT01434680已完成2 期
A Phase 2, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of the New Liquid Formulation of Novartis Meningococcal C Conjugate Vaccine and of the Novartis Lyophilized Meningococcal C Conjugate Vaccine Manufactured at Two Different Sites, in Healthy Toddlers
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 992
- 试验地点
- 11
- 主要终点
- Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination
研究概览
简要总结
The study was to evaluate the safety and and immune response of each of three lots of Novartis Meningococcal C Conjugate Vaccine (MenC-CRM Liquid) when administered to Healthy Toddlers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 12 Months 至 23 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy 12 - 23 (inclusive) month-old male or female toddlers.
- •A parent/legal guardian was given written informed consent after the nature of the study has been explained.
- •Available for both the visits scheduled in the study.
- •In good health as determined by medical history, physical examination and clinical judgment of the investigator.
排除标准
- •History of any meningococcal vaccine administration.
- •Previous known or suspected disease caused by N. meningitidis.
- •Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.
- •History of severe allergic reaction after previous vaccinations, allergy to Latex, or hypersensitivity to any component of the vaccine.
- •Significant acute or chronic infection within the previous 7 days or axillary temperature ≥38.0°C within the previous 3 days.
- •Individuals who have received antibiotics within 6 days before vaccination.
- •Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from (for example):
- •Receipt of any immunosuppressive therapy at any time since birth.
- •Receipt of any immunostimulants at any time since birth.
- •Receipt of any systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth (use of topical corticosteroids administered in limited areas of the body [for example, eczema on knees or face or elbows] is allowed).
- •Immune deficiency disorder, or known HIV infection.
- •History of seizure, any progressive neurological disease or Guillain Barré Syndrome (exception: one self-limited non-medicated febrile seizure is acceptable).
- •Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.
- •Taken any antipyretic medication in the previous 6 hours.
- •Received any other vaccines within 30 days prior to enrollment or intent to receive any other vaccine during the study (Exception: Inactivated influenza vaccine may be administered up to 15 days prior to study immunization and no less than 15 days after study immunization).
- •Toddler's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
- •Participation in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study during this study.
- •Family members or household members of site research staff.
- •History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- •Any serious chronic or progressive disease according to judgment of the investigator (neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
结局指标
主要结局
Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination
时间窗: 1 month postvaccination (day 29)
Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs)against N meningitidis type C, at day 29 after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM EMV and MenC-CRM ROS to MenC-CRM EMV.
次要结局
- Geometric Mean hSBA Titers Against N Meningitidis Serogroup C 28 Days After Vaccination(1 month postvaccination (day 29))
- Number Of Subjects Reporting Solicited Local And Systemic Adverse Events(From day 1 through day 7)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsMeningococcal InfectionsMeningococcal MeningitisNCT00450437Novartis Vaccines3,539
已完成
3 期
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.Meningococcal DiseaseNCT01973218Novartis Vaccines264
已完成
2 期
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsMeningococcal DiseaseNCT00560313Novartis Vaccines54
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)Pneumococcal InfectionsNCT02987972Merck Sharp & Dohme LLC1,051
终止
2 期
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)Ulcerative ColitisNCT00307827Abbott38